NeuroOne Medical Technologies Corp

NeuroOne Medical Technologies Corp. is a medical technology company, which engages in the development and commercialization of thin film electrode technology for continuous electroencephalogram and stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company was founded by Mark Christianson on August 20, 2009 and is headquartered in Eden Prairie, MN.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

NeuroOne Medical Technologies Corp excels in Q2 2024 performance

NeuroOne Medical Technologies Corp demonstrated strong commercial and financial performance in Q2 2024.
The company's focus on innovation, strategic partnerships, and diverse product development is driving growth.
While facing challenges in capital management and market competition, NeuroOne is well-positioned for future success.
Opportunities in product diversification, market expansion, and fundraising set the stage for continued growth and profitability.

NeuroOne Medical Technologies Corp reports strong Q3 performance and expansion opportunities

NMTC's Q3 2024 performance reflects progress in commercialization and product revenue growth, supported by strategic financing initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to capitalize on distribution agreements and product expansion.
With a focus on innovation and market penetration, NMTC is poised for growth through new FDA applications and leveraging its technological advancements.

NeuroOne Medical Technologies Corp achieves FDA clearance and revenue growth

NeuroOne Medical Technologies Corp made significant strides in product development, securing partnerships, and achieving FDA clearance, positioning the company for growth.
While facing challenges in stock price compliance and market competition, the company's focus on innovation and revenue growth presents opportunities for expansion.
With a strong financial performance in 2024 and revenue growth projections for 2025, NeuroOne is poised to capitalize on market demand and technological advancements.
By diversifying product applications and exploring new partnerships, NeuroOne aims to drive market penetration and establish itself as a key player in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q4 2024 Earnings Conference Call December 17, 2024 9:00 AM ET Company Participants Dave Rosa - Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Operator Good day, ladies and gentlemen. Welcome to the NeuroOne Fourth Quarter and Fiscal Year-End 2024 Earnings Call.

NeuroOne Medical Technologies Corporation (NMTC) Q4 2024 Earnings Call Transcript

Company's Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly

NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025

NeuroOne is a commercial stage medical device company with FDA-cleared electrodes used in prominent U.S. medical centers for epilepsy diagnosis and treatment. NMTC is partnered with Zimmer Biomet, a $21 billion medical device company, and is close to reaching cash flow break even, reducing shareholder dilution. NMTC's electrodes are superior due to their ability to provide real-time, high-resolution brain signal recordings and stimulate brain tissue, aiding in precise neurosurgical procedures.

NeuroOne Medical Technologies: A Small-Cap Electrode Technology Play With Multiple Catalysts Ahead

EDEN PRAIRIE, MN / ACCESSWIRE / November 13, 2024 / NeuroOne Medical Technologies Corporation (Nasdaq:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in the Virtual Investor Summit Microcap Event. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.

NeuroOne Medical Technologies Corporation to Present at November 21st Virtual Investor Summit Microcap Event

License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS MarketsAgreement expected to boost NeuroOne sales revenue and profitability

NeuroOne® Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF™ Ablation System

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference

EDEN PRAIRIE, Minn., Sept. 24, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that its percutaneous paddle technology will be featured at The Business of Pain Meeting September 26th – 29th at the Loew's Vanderbilt Hotel in Nashville, TN.

NeuroOne® Spinal Cord Stimulation Electrode Technology to be Featured at The Business of Pain Conference

Forty-four ablations performed successfully in one patient Patient currently reportedly seizure free with improvements in mood and memory EDEN PRAIRIE, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the OneRF Ablation System was recently used in a breakthrough patient procedure at the University Hospitals in Cleveland to successfully complete forty four ablations in one patient.

NeuroOne® Announces Breakthrough Case Completed with OneRF™ Ablation System at the University Hospitals in Cleveland

EDEN PRAIRIE, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its upcoming virtual investor presentation at the H.C. Wainwright 26th Annual Global Investment Conference being held in-person and virtually on September 9-11, 2024.

NeuroOne® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q3 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Dave Rosa - Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Operator Good day, ladies and gentlemen. Welcome to the NeuroOne Medical Technologies Corporation Third Quarter of Fiscal Year 2024 Financial Results Conference Call.

NeuroOne Medical Technologies Corporation (NMTC) Q3 2024 Earnings Call Transcript

EDEN PRAIRIE, Minn., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter fiscal year 2024 ended June 30, 2024.

NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on August 14, 2024, at 4:30 PM Eastern Time to discuss financial results for its third quarter of fiscal year 2024 ended June 30, 2024, and provide a corporate update.

NeuroOne® to Report Third Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on August 14

Vertex Pharmaceuticals

Problems with the central nervous system are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it's extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website Labiotech reported last year.

The 3 Best Neuroscience Biotech Stocks to Buy Now

Medtronic

Neuronetics Inc

If the prospect of controlling computers and robots with brainpower alone excites you, neurotech stocks are right up your alley. Unfortunately, today's top neurotech company — Elon Musk's Neuralink — remains off-limits to retail investors.

3 Neurotech Stocks Bridging Mind and Machine

ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024

NeuroOne® Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q2 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Dave Rosa - President & Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Operator Good day, ladies and gentlemen. Welcome to the NeuroOne Medical Technologies Corporation Second Quarter of Fiscal Year 2024 Financial Results Conference Call.

NeuroOne Medical Technologies Corporation (NMTC) Q2 2024 Earnings Call Transcript

EDEN PRAIRIE, Minn., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter fiscal year 2024 ended March 31, 2024.

NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on May 14, 2024 at 4:30 PM Eastern Time to discuss financial results for its second quarter of fiscal year 2024 ended March 31, 2024, and provide a corporate update.

NeuroOne® to Report Second Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on May 14

EDEN PRAIRIE, Minn., April 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces an appearance by Chief Executive Officer Dave Rosa on Bloomberg Television's Bloomberg Technology. A replay of the segment, which aired live yesterday, can be viewed at NeuroOne-Bloomberg.

NeuroOne® CEO Dave Rosa Featured on Bloomberg Technology

First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control

NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes

EDEN PRAIRIE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces an appearance by Chief Executive Officer Dave Rosa on Fox Business Network's Varney & Co. on Wednesday April 3rd. The segment, which aired live yesterday, can be viewed online at Fox Business .

NeuroOne® CEO Dave Rosa Featured on Fox Business Network's Varney & Co.

NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System

EDEN PRAIRIE, Minn., March 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the 36th Annual Roth Conference being held March 17-19, 2024 in Dana Point, California. Chief Executive Offer Dave Rosa and Chief Financial Officer Ron McClurg will host one-on-one meetings with institutional investors and analysts on Monday, March 18th and Tuesday, March 19th.

NeuroOne® to Participate in the 36th Annual Roth Conference

EDEN PRAIRIE, Minn., Feb. 23, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announced that, effective February 23, 2024, the Compensation Committee of the Board of Directors approved an equity award under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the “Inducement Plan”), as a material inducement to one individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of awards that are not made under a stockholder approved equity plan.

NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NeuroOne Medical Technologies Corporation (NMTC) Q1 2024 Earnings Call Transcript

News for NeuroOne Medical Technologies Corp Stock (NMTC)